Browser does not support script.
Skip to main content
Responding to the decision by NICE to recommend Thalidomide and Bortezomib as first-line treatments for patients with multiple myeloma, a type of cancer that affects cells in the bone marrow, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
'It is great news that NICE has recommended these drugs for cancer patients with multiple myeloma and that their needs have been listened to.
'Of the two million people living with a cancer diagnosis in the UK over 900,000 (45%) have a rarer cancer . For too long patients with less common cancers, such as multiple myeloma have lost out on receiving the vital medicines they need on the NHS.
'This decision recognises the need to fund drugs that improve the quality and length of life for cancer patients with rarer cancers, which is a key step to improving better access to treatments for all.'
If you have any questions about Macmillan we would love to hear from you| .
You can also follow us| on Facebook, Twitter, Flickr or YouTube.
© Macmillan Cancer Support 2013
what are these?|